Dashboard
Manage Tickers

KPTI Karyopharm Therapeutics Inc.

Nasdaq karyopharm.com


$ 6.07 $ 0.27 (4.66 %)    

Monday, 03-Nov-2025 15:59:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 6.07
$ 5.80
$ 5.63 x 30
$ 6.35 x 1,075
$ 5.66 - $ 6.17
$ 3.51 - $ 14.24
198,187
na
103.5B
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 02-19-2025 12-31-2024 10-K
5 11-05-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-17-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-24-2021 12-31-2020 10-K
21 11-02-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-26-2020 12-31-2019 10-K
25 11-04-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-15-2018 12-31-2017 10-K
33 11-02-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

karyopharm-therapeutics-files-prospectus-for-resale-from-time-to-time-of-up-to-957m-common-stock-by-selling-stockholders
Karyopharm Therapeutics Files Prospectus F...
11/03/2025 22:18:33

- SEC Filing

karyopharm-therapeutics-affirms-fy2025-sales-guidance-of-140000m-155000m-vs-149328m-est
Karyopharm Therapeutics Affirms FY2025 Sal...
11/03/2025 13:01:11

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2025 sales outlook from $140.000 million-$155.000 million to $140.000 million-$...

karyopharm-therapeutics-q3-eps-382-misses-313-estimate-sales-44000m-beat-41212m-estimate
Karyopharm Therapeutics Q3 EPS $(3.82) Mis...
11/03/2025 12:32:59

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(3.82) per share which missed the analyst consensus estimat...

earnings-scheduled-for-november-3-2025
Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

karyopharm-therapeutics-earnings-preview
Karyopharm Therapeutics Earnings Preview
10/31/2025 21:02:11

this-palo-alto-networks-analyst-turns-bullish-here-are-top-5-upgrades-for-monday
This Palo Alto Networks Analyst Turns Bull...
10/13/2025 11:48:50

hc-wainwright--co-upgrades-karyopharm-therapeutics-to-buy-announces-15-price-target
HC Wainwright & Co. Upgrades Karyopharm Th...
10/13/2025 11:23:41

HC Wainwright & Co. analyst Robert Burns upgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Neutral to Buy and announce...

piper-sandler-reiterates-overweight-on-karyopharm-therapeutics-lowers-price-target-to-12
Piper Sandler Reiterates Overweight on Kar...
10/09/2025 14:17:44

Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the pric...

baird-maintains-outperform-on-karyopharm-therapeutics-lowers-price-target-to-21
Baird Maintains Outperform on Karyopharm T...
10/09/2025 12:08:17

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from...

karyopharm-strengthens-balance-sheet-with-100-million-financing-to-extend-cash-runway-into-2026
Karyopharm Strengthens Balance Sheet With ...
10/08/2025 17:31:59

Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and adva...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/08/2025 12:09:23

karyopharm-therapeutics-says-top-line-data-from-phase-3-sentry-trial-in-myelofibrosis-on-track-for-march-2026
Karyopharm Therapeutics Says Top-Line Data...
10/08/2025 11:27:39

karyopharm-therapeutics-expects-q3-preliminary-total-revenue-of-42m---44m-and-us-xpovio-net-product-revenue-of-32m
Karyopharm Therapeutics Expects Q3 Prelimi...
10/08/2025 11:23:17

karyopharm-therapeutics-says-top-line-data-from-phase-3-sentry-trial-in-myelofibrosis-is-on-track-for-march-2026
Karyopharm Therapeutics Says Top-Line Data...
10/08/2025 11:07:03

karyopharm-secures-100m-of-financial-flexibility-and-additional-capital-to-extend-cash-runway-into-q2-2026
Karyopharm Secures $100M Of Financial Flex...
10/08/2025 11:04:44

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 21:06:04

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 17:06:52

karyopharm-completes-enrollment-in-phase-3-trial-testing-new-combo-therapy-for-myelofibrosis-patients
Karyopharm Completes Enrollment In Phase 3...
09/10/2025 11:02:57

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today ...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/08/2025 21:07:27

baird-maintains-outperform-on-karyopharm-therapeutics-lowers-price-target-to-25
Baird Maintains Outperform on Karyopharm T...
08/12/2025 11:41:22

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION